This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Source of effectiveness data
The effectiveness evidence was derived from a single study.
Link between effectiveness and cost data
The costing was carried out prospectively on the same sample of patients as that used in the effectiveness analysis.
Study sample
Power calculations were performed in the preliminary phase of the study. These suggested that 200 patients in each treatment group would be required to detect differences of 5 mmHg in systolic BP, or 2 mmHg in diastolic BP, with 85% power at a 5% significance level. Of the 606 patients who were assessed for eligibility at the study institutions, 206 were excluded. Reasons for exclusion were office diastolic BP less than 95 mmHg (112), did not meet other inclusion criteria (17), consent not given (50), and unavailable for follow-up (27) . This left a sample of 400 patients for allocation to the two study groups. One hundred and ninety-seven patients (51.8% women) were assigned to the office group and 203 (52.7% women) to the home group. The mean age of the patients was 52.6 (+/-12.0) years in the office group and 54.2 (+/-12.1) years in the home group, and the body mass index (BMI) was 27.7 (+/-4.4) and 28.5 (+/-4.7), respectively.
Study design
This was a prospective, blinded, randomised clinical trial that was carried out at 56 primary care practices and 3 hospital-based outpatient clinics in Belgium and 1 specialised hypertension clinic in Dublin, Ireland. The patients were stratified by centre and were then randomised to study groups using a computerised random-number function. The length of follow-up was 1 year. Follow-up visits were scheduled at 1 and 2 months and thereafter at 2-month intervals. The number of patients who withdrew from the study was 26 in the office group (10 missed at least 1 follow-up visit and 16 dropped out) and 27 in the home group (11 missed at least 1 follow-up visit, 14 dropped out, and 2 experienced adverse events). A physician at the coordinating centre, who was blinded to randomisation, made all treatment decisions on the basis of the BP measurements he received. The field investigators then implemented his treatment decisions.
Analysis of effectiveness
The analysis of the clinical study appears to have been conducted on an intention to treat basis since all patients included in the initial study sample were considered in the analysis of effectiveness. The outcome measures used were treatment intensity, BP control, patient compliance, symptoms, major adverse events and left ventricular mass. Symptoms were assessed using a score based on 33 questions. The study groups were comparable at baseline in terms of their demographics and BP values.
Effectiveness results
More home than office patients could stop antihypertensive drug treatment, as their diastolic BP was less than 80 mmHg and thereafter stabilised at or below the target range (25.6% versus 11.3%; 2.2 versus 1.0 patients per 100 followed up for 1 month; p<0.001). An opposite trend was observed for patients proceeding to multiple-drug treatment (38.7% versus 45.1%; 3.3 versus 3.8 patients per 100 followed up for 1 month; p=0.14). A further analysis showed that in the home BP group, a lower home diastolic BP at entry and the lack of previous treatment independently predicted permanent cessation of antihypertensive drug therapy. However, in the office BP group, only the lack of previous treatment predicted stoppage of antihypertensive treatment.
BP control was better in the office group than in the home group. In particular, after adjusting for baseline BP, gender, age and BMI, the final differences between the two treatment groups ranged from 4.8 to 6.8 mmHg for systolic BP and from 2.9 to 3.5 mmHg for diastolic BP. For example, the difference between groups in the decrease in 24-hour systolic BP was 4.9 mmHg (95% confidence interval, CI: 2.5 -7.4; p<0.001) in favour of the office group. Similarly, the difference between groups in the decrease in 24-hour diastolic BP was 2.9 mmHg (95% CI: 1.4 -4.4; p<0.001), again in favour of the office group.
In terms of patient compliance, office patients and home patients with available pill counts (159 and 169, respectively) took similar percentages of the prescribed dosages of the study medications (89.3% versus 90.1%; p=0.90).
No statistically significant differences in symptoms, adverse events and left ventricular masses were observed between the groups. At the end of the trial, there was a marginal benefit only for the echocardiographic E:A ratio in the office group compared with the home group (change of 0.15 in the office group and change of -0.07 in the home group; p=0.02).
Clinical conclusions
The effectiveness analysis showed that BP control was better in office patients than in home patients, although more individuals in the latter group could stop antihypertensive treatment.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic analysis. In effect, a cost-consequences analysis was carried out.
Direct costs
The analysis was carried out from the perspective of the Belgian health insurance system. It included physician fees, drug acquisition costs, and the depreciation rate of the home BP measurement device. The unit costs were reported, but information on quantities of resources used was not given for all items. Resource use was estimated using data derived from the sample of patients included in the clinical trial. The source of the costs was not explicitly stated, but the costs were likely to reflect monetary rates of the Belgian health insurance system. Assumptions about resource use were clearly reported. Discounting was not relevant since the costs per patient were incurred during a 1-year period. The price year was 2002.
Statistical analysis of costs
Standard statistical analyses were performed to test the statistical significance of cost-differences.
Indirect Costs
The indirect costs were not included.
Currency
Euros (EUR). The exchange rate from Euros into US dollars ($) on January 2004 was EUR 1 = $1.27.
Sensitivity analysis
Sensitivity analyses were not performed.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total costs per 100 patients for treatment for 1 month were EUR 3,875 (+/-1,723) in the office BP group and EUR 3,522 (+/-1,747) in the office BP group. The difference of EUR 353 (+/-175) was statistically significant, (p=0.04).
In general, office BP was associated with higher physicians and drug costs that were not completely offset by the higher cost of monitoring associated with home BP.
